Meningiomas are the most common primary nervous system tumor. The tumor suppressor NF2 is disrupted in approximately half of all meningiomas 1 , but the complete spectrum of genetic changes remains undefined. We performed whole-genome or whole-exome sequencing on 17 meningiomas and focused sequencing on an additional 48 tumors to identify and validate somatic genetic alterations. Most meningiomas had simple genomes, with fewer mutations, rearrangements and copynumber alterations than reported in other tumors in adults. AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. These mutations were present in therapeutically challenging tumors of the skull base and higher grade. These results begin to define the spectrum of genetic alterations in meningiomas and identify potential therapeutic targets.
Meningiomas, tumors that arise from the arachnoidal cap cells of the leptomeninges, constitute approximately one-third of primary central nervous system (CNS) tumors 1 . Most meningiomas (80%) are World Health Organization (WHO) grade I and are treated by surgical resection. However, resection of some meningiomas, particularly at the skull base, is associated with high morbidity. Moreover, 18% of these tumors recur within 5 years, and patients with grade I tumors have significantly reduced long-term survival that is related to both tumor recurrence and stroke risk 2 . Recurrence rates for grade II and III meningiomas can be as high as 40% and 80%, with 5-year overall survival of approximately 76% and 32%, respectively 1, 3, 4 . Although there are recent reports of a stepwise progression of a subset of grade I meningiomas to higher grades 5, 6 , these secondary grade II and III meningiomas may differ fundamentally from spontaneously arising grade II and III tumors. Radiation is frequently used as an adjunct to surgery; however, there are no effective chemotherapeutic options when surgery and radiation fail to offer durable long-term disease control 7 .
We sequenced DNA from a discovery set of grade I meningiomas using whole-genome (n = 11) and whole-exome (n = 6) techniques to identify somatic copy-number alterations (SCNAs), rearrangements, mutations and insertions and/or deletions (indels) throughout the genome. We then sequenced 645 known cancer-associated genes, including genes altered in the discovery set, in a validation set of 30 additional grade I tumors. We also sequenced these genes in an extrapolation set of 18 grade II or III meningiomas to evaluate whether findings in grade I tumors extended to tumors of higher grade (Online Methods and Supplementary Tables 1 and 2) .
Meningiomas in the discovery set had a small number of somatic genetic events compared to other tumor types [8] [9] [10] [11] [12] [13] [14] . We sequenced to high depth (median coverage of 57× for the genome, 181× for the exome and 154× for the validation and extrapolation) and used largeinsert libraries in whole-genome samples (500 bp and 800 bp) to optimize our detection of rearrangements and other events. Nevertheless, we found that the median meningioma had SCNAs affecting only 3.3% of the genome, one rearrangement and eight nonsynonymous mutations. Among mutations, cytosine-to-thymidine transitions within a CpG context predominated, consistent with spontaneous deamination (Supplementary Fig. 1a ) 15 . The rates of alteration we observed in meningiomas were significantly lower (often by a factor of ten or more) than previously determined rates for other tumors that have been sequenced to lower depth and with smaller insert sizes ( Fig. 1a-c) . These findings may reflect differences in mitotic index, l e t t e r s prior treatments or carcinogen exposure between these tumor types.
In contrast, rates of genomic disruption were higher in the grade II and III meningiomas in the extrapolation set than for their grade I counterparts ( Supplementary Fig. 2) . The mean rate of nonsynonymous mutation within the 645 sequenced genes was nearly twice as high in higher-grade tumors (3.0 versus 1.6; P < 0.02), and the proportion of the genome affected by SCNAs was markedly higher (median of 12.8% versus 0.3%; P < 0.001).
Among SCNAs, loss of chromosome 22 (containing NF2) was the most frequent genetic alteration in the discovery cohort, occurring in all ten tumors with focal NF2 alteration (defined as mutation, indel or rearrangement within the NF2 locus) and one without ( Fig. 1d and Supplementary Fig. 3 ). The association between NF2 mutation and chromosome 22 loss extended to the validation and extrapolation sets (P < 0.0001) and confirms previous reports using other methods 16 . In the grade I tumors, we also found recurrent significant losses on 1p, 7p, 14p and 19 and gains on chromosomes 5 and 20 (q < 0.1), some of which have been described previously 17 . Higher-grade tumors of the extrapolation set had additional recurrent losses on 10q and 14q, previously reported in atypical and anaplastic meningiomas 1 . We did not observe previously described losses of FPB41L3 (also known as DAL-1), a gene related to NF2 on 18p (ref. 18 ).
We identified a total of 110 candidate somatic rearrangements in samples that underwent whole-genome analysis, of which 93 were confirmed to have reads spanning the putative fusion site ( Supplementary Fig. 4 and Supplementary Table 3 ). Most of these rearrangements were concentrated in three tumors ( Fig. 2) , one of which had chromothripsis-the simultaneous rearrangement of one or more chromosome, estimated to occur in 2-3% of aggressive malignancies 19, 20 . One of the genes disrupted by chromothripsis was the putative tumor suppressor NEGR1, which was also rearranged in a second tumor. NEGR1 has a role in CNS development and is recurrently deleted in neuroblastoma 21 , although its role in tumorigenesis remains to be elucidated. A third sample harbored disruptions in the known and putative tumor suppressors NF1, NF2 and CDK14. A copy-neutral 12.5-Mb inversion caused reciprocal fusion of NF2 (before exon 2) and TCF20, representing a new mechanism of NF2 inactivation in meningiomas. We also identified other translocations 
Synonymous Nonsynonymous npg l e t t e r s in samples that were not subjected to wholegenome analysis, including a truncating translocation in CHEK2 ( Supplementary Fig. 4i and Supplementary Table 3 ). The loss of CHEK2 may lead to impaired DNA repair, as has been described in meningioma cell lines 22 .
Number of mutations in exons
The most frequently mutated gene was NF2, which exhibited a total of nine nonsense mutations, nine splice-site mutations and nine frameshift indels in addition to the above-mentioned translocation ( Supplementary Fig. 5 ). The majority of these events overlapped with previously reported events, and our rates of NF2 inactivation were consistent with published rates 1 . The nonsynonymous mutation rates of tumors with and without focal NF2 alterations did not differ significantly, nor did the spectra of their mutation subtypes ( Supplementary Fig. 1b-d) .
We also identified nonsynonymous mutations in 190 other genes ( Supplementary Tables 4 and 5) . We determined the significance of mutation rates in individual genes relative to genome-wide background rates of mutation. Six genes reached statistical significance ( Fig. 3, Supplementary Fig. 5 and Supplementary Table 4 ). Four of these (NF2, KDM5C, SMO and AKT1) have previously been implicated in cancer, and the other two (RGPD3 and CD300C) have not. Isolated or rare mutations that did not reach significance across the entire cohort were observed in 23 genes with known involvement in cancer, including TP53, APC, CBL, STK11 and NOTCH2.
Among genes mutated in our cohort and previously associated with cancer, three (KDM5C, KDM6A and SMARCB1) are epigenetic modifiers. Mutations involving these genes affected 8% of the cohort. Both KDM5C (also known as JARID1C) and KDM6A are histone demethylases 23 ; SMARCB1 (also known as SNF5 and INI1) is a member of the SWI/SNF chromatin-remodeling complex. SMARCB1 is located 6 Mb away from NF2, and a four-hit model of biallelic inactivation of both genes has been described in familial schwannomas 24 . The mutation we identified (encoding a p.Arg374Gln alteration) is near a mutational hotspot (p.Arg377His) described in meningiomas 25 , and germline mutations in SMARCB1, including ones encoding a p.Arg374Gln alteration, have been reported in the congenital disorder Coffin-Siris syndrome 26 .
We observed mutations of SMO, a member of the Hedgehog signaling pathway, in three tumors (5%). None of these tumors had focal alteration of NF2. Two samples harbored a mutation in SMO encoding a p.Trp535Leu alteration, a known oncogenic mutation in basal-cell carcinomas 27 , and a third harbored a mutation encoding a p.Leu412Phe alteration, previously reported in desmoplastic medulloblastoma 28 . The allelic fractions of these mutations (45%, 55% and 47%, respectively) were among the highest in these tumors, suggesting clonality. Moreover, dysregulation of the Hedgehog pathway has previously been described in meningiomas 29, 30 Figure 3 Significant and selected cancer-related somatic mutations, indels and translocations in meningiomas. Mutation subtypes are denoted by color. If multiple mutations were found in a gene in a single sample, only one is shown. Discovery set tumors are shown in the same order as in Figure 1d . The significance of mutations in each gene is shown to the right by false discovery rate (FDR) q value. The full list of mutated genes is given in supplementary table 4. npg l e t t e r s mutation (upstream of SMO) and is characterized by predisposition to multiple cancers, including desmoplastic medulloblastomas and meningiomas 31, 32 . Although we did not observe somatic mutations in PTCH1, two samples harbored germline alterations that were also present in the tumors (encoding p.Asp436Asn and p.
SMO-mutated meningioma
[Glu44Gly]+ [Pro1282Leu] alterations). However, these individuals did not exhibit manifestations of Gorlin syndrome, such that the functional relevance of these specific events is unclear.
Six samples had mutations of the phosphatidylinositol 3-kinase (PI3K)-AKT-mTOR pathway. None of these had mutations of NF2 or SMO (P = 0.03). Five samples harbored identical AKT1 mutations (p.Glu17Lys) known to be oncogenic in breast, colorectal and lung cancers 33 . The glutamic acid-to-lysine substitution results in constitutive AKT1 activation, which stimulates downstream mTOR signaling. The sixth sample had a new MTOR mutation (encoding a p.Asp1279Val alteration).
The mutations in the Hedgehog and PI3K pathways were also associated with particular histopathological subtypes ( Fig. 4) . Meningiomas with mutated SMO and AKT1-MTOR were predominantly of the meningothelial subtype (P = 0.009 and 0.005, respectively, Fisher's exact test). This is in contrast to the grade I NF2-altered tumors, which were predominantly fibroblastic and/or transitional (P = 0.013), consistent with previous reports 34 . We did not find statistically significant correlations with other clinically relevant variables, including age, tumor location or previous resection. However, one AKT1-and two SMO-mutated tumors were resected from the skull base, a region that offers particular challenges to resection and higher rates of recurrence 35 ( Supplementary Table 5 ).
To validate these findings, we also genotyped an additional 46 grade I and 49 grade II or III meningiomas for AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu and p.Leu412Phe) mutations using a mass spectrometrybased method (Sequenom hME). We found one SMO mutation (p.Leu412Phe) and three additional AKT1 mutations (p.Glu17Lys) (Supplementary Table 6 ). One of the latter was in a grade III tumor, and the remaining three were in skull base tumors, of which two were of meningothelial histology.
Mutations in SMO, AKT1 and MTOR also correlated with the presence of markers of pathway activation. GAB1 immunoreactivity is used in medulloblastomas to characterize tumors with Hedgehog pathway activation 36 . Of the 65 meningiomas, 7 exhibited strong immunoreactivity for GAB1, including the 3 tumors harboring SMO mutations (P = 0.0008). The other four GAB1-positive tumors were grade II meningiomas. Likewise, STMN1 expression is a marker of PI3K-AKT pathway activation 37 . Ten meningiomas exhibited strong STMN1 expression, including all six AKT1-and MTOR-mutated meningiomas (P = 3 × 10 −6 ). Notably, all 3 SMO-mutated meningiomas also exhibited strong (n = 2) or moderate (n = 1) STMN1 staining. This is consistent with studies that have suggested that the Hedgehog and PI3K-AKT-mTOR pathways may interact 38 .
We observed recurrent mutations in signaling pathways and epigenetic modifiers, but our data also highlight the heterogeneity of mutations in these tumors. Among the 17 tumors we comprehensively characterized, 3 (18%) did not have mutations in any of the significantly mutated genes. Genomic characterization of additional tumors, particularly those of higher grade, is likely to reveal additional oncogenic mechanisms.
These observations also have the potential to guide new therapeutic strategies. We observed SMO and AKT1 mutations in tumors that pose special therapeutic challenges, including one high-grade and six skull-base tumors. Inhibitors of SMO have generated high response rates in patients with basal-cell carcinoma, many of which are driven by Hedgehog pathway mutations 39 . Likewise, inhibitors of the PI3K-AKT-mTOR pathway have shown promise in preclinical and clinical trials in multiple cancer types 40 . The paucity of additional genetic events in meningiomas harboring mutations of the PI3K and Hedgehog signaling pathways suggests that patients with these meningiomas may benefit from such targeted therapies already in development or use.
oNLINe MeTHods
Sample selection and preparation. This study was reviewed and approved by the human subjects institutional review boards (IRBs) of the Dana-Farber Cancer Institute, Brigham and Women's Hospital and the Broad Institute of Harvard and MIT. Written informed consent was obtained from all participants (Supplementary Note). We chose to initially perform whole-exome sequencing in 6 meningiomas as a pilot study to determine the optimal depth of whole-genome sequencing needed to provide adequate tumor coverage in spite of stromal contamination. These 6 tumors and 11 additional meningiomas on which whole-genome sequencing was performed comprised the discovery cohort. To validate clinically actionable mutations identified in the discovery set, we performed focused sequencing on a validation cohort consisting of an additional 30 grade I meningiomas. We also assembled an extrapolation cohort of 15 grade II and 3 grade III meningiomas ( Supplementary Table 1 ) to compare genetic aberrations in low-and high-grade tumors. Our approach of deep, broad sequencing of a small representative cohort followed by validation in an independent larger group is similar to the approach used by others to discover IDH1 (ref. 41 ) and PIK3CA 42 mutations. Three study pathologists reviewed the histopathological diagnosis, grade and purity of each tumor.
Representative fresh-frozen blocks with estimated purity of ≥90% were selected. DNA was extracted from tissue shavings and buffy coat preparations of paired blood using standard techniques (Qiagen), then quantified using PicoGreen dye (Invitrogen). The identities of tumor-normal pairs were confirmed by mass spectrometry genotyping using a well-established 48-SNP panel (Sequenom) 43 .
Sequencing. For whole-genome sequencing (n = 11), DNA was randomly fragmented, and libraries of two insert sizes were prepared (500 and 800 bp) for paired-end sequencing on an Illumina HiSeq 2000 (refs. 10, 11) . Target depth (60× for tumors, 30× for normal samples) was achieved in all but one sample (MEN0015) that failed 800-bp library preparation; however, adequate coverage of the 500-bp library was achieved.
For whole-exome sequencing (n = 6), 250-bp libraries were prepared by Covaris sonication, double size selected (Agencourt AMPure XP beads) and ligated to specific barcoded adaptors (Illumina TruSeq) for multiplexed analysis. Exome hybrid capture was performed with NimbleGen SeqCap EZ Exome Library SR v2.2, Agilent SureSelect All Exon v2.0 hybrid capture kit or with both approaches. All samples but one achieved >150× coverage in exon regions (MENex004; 79× for the tumor, 90× for the normal sample).
We proceeded with sequencing 645 cancer-associated genes in our larger validation and extrapolation sample set (n = 48) because this preselected gene set (OncoPanel) included all genes of interest that were also clinically actionable (including AKT1 and SMO) in which mutations were identified in the discovery set. In addition, a wide breadth of other genes in the same families (such as MTOR in the AKT pathway) and other interesting cancer-related genes in other families were included ( Supplementary Table 2 ). Briefly, DNA was sonicated to achieve an average fragment size of 150 bp and was then size selected and barcoded as described. Each multiplexed pool was hybridized with biotinylated baits (Agilent SureSelect) designed to capture exonic sequences. Streptavidin-coated beads were used to pull down the complexes, which were loaded on a HiSeq 2000 for paired-end sequencing.
Sequencing analysis pipeline.
For exome-and OncoPanel-sequenced data, pooled sample reads were demultiplexed using Picard tools. Read pairs were aligned to the hg19 reference sequence (Build 37) using the Burrows-Wheeler Aligner 44 with options −q 5 −l 32 −k 2 −o 1. Data were sorted and duplicates were marked using SAMtools and Picard. Biases in base quality score assignments due to flow cell, lane, dinucleotide context and machine cycle were analyzed and recalibrated, and local realignment around indels was achieved using the Genome Analysis Toolkit (GATK) 45, 46 .
Variant and germline calling were performed within the Firehose environment 11 using GenePattern 47 . All algorithms described are available publicly (see URLs). All sample pairs passed a quality control pipeline to test for any tumor-normal and interindividual mix-ups by comparing insert-size distributions and copy-number profiles, as described previously 10 . The Mann-Whitney test was used to determine the significance of differences between rates of somatic genetic alteration between meningiomas and the other data sets.
SCNAs and rearrangements. SCNAs were evaluated using SegSeq 48 , which uses a combination of local change-point analysis and subsequent merging of adjacent chromosomal segments with similar copy number. For arm-level significance analysis, pseudo-markers were added every 10,000 bases to segmented copy-number data, and these were analyzed by GISTIC 2.0 to determine which events occurred more often than expected by chance 14 .
Rearrangements and their exact breakpoints were identified using a combination of dRanger and BreakPointer algorithms 8, 10 . Briefly, dRanger identified potential rearrangements from read pairs mapping to different chromosomes or to unexpected positions or orientations on the same chromosome, and BreakPointer located reads spanning a fusion and maps the exact breakpoint using modified Smith-Waterman alignment 10 . Rearrangements were assigned a score reflecting the number of tumor reads supporting a breakpoint, the fraction of nearby reads with MAPQ0, the prevalence of other nearby discordant pairs and the standard deviation of breakpoint starting positions. To minimize false positive rearrangements, only breakpoints with a score of ≥8 passing BreakPointer were accepted. The specificity of this type of approach has previously been shown to be >90% (ref. 10) . Copy-number and rearrangement results were displayed using the Circos program 49 .
Identification of base-pair substitutions and short indels.
Mutations were only considered at covered positions (≥8× for normal samples, 14× for tumor sites). Somatic mutations and short indels were called and filtered using MuTect and IndelLocator 10, 11 . These variations were annotated to genes and compared to events in the Catalogue of Somatic Mutations in Cancer (COSMIC) using Oncotator, and spurious calls caused by errors in mapping and other previously identified systematic errors were removed using an established list of known problematic sites [11] [12] [13] . MutSig was used to determine the significance of mutated genes, adjusting for cohort-and genome-wide mutation rates, local background mutation rate and gene length [11] [12] [13] . We used a cohort-wide background mutation rate instead of the more commonly used sample-specific mutation rate because the observed low mutation rate in these tumors leads to poor sampling of individual mutation subcategories. This may lead to overly large apparent variations between the background rates of mutation subtypes in different samples. Mutations are shown in the context of UniProt regions and domains. Post-hoc analyses for significant non-overlap of NF2, SMO and AKT1 mutations was performed by Fisher's exact test, as were associations between these mutations and chromosome 22 loss or specific categorical demographic characteristics. The Mann-Whitney test was used for comparisons of mutations and continuous demographic variables.
Germline variants were called using the UnifiedGenotyper 45, 46 , filtered against the 1000 Genomes Project data set 50 and annotated to genes as described. Genes with known syndromic associations to meningiomas (NF1, NF2, SMARCB1 and PTCH1) were manually reviewed for germline nonsynonymous mutations. These were visualized in the Integrative Genomics Viewer.
Sequenom validation.
We obtained IRB approval for the collection of independent archival paraffin-embedded meningioma samples from the Brigham and Women's Hospital Pathology Department. We identified 95 samples that did not overlap with our cohort of 65 tumors, resected between 2005 and 2012. Forty-nine of these were higher-grade meningiomas. Tissue was deparaffinized and DNA extracted using standard techniques (Qiagen). Variants in SMO (p.Trp535Leu and p.Leu412Phe) and AKT1 (p.Glu17KLys) were assayed using Sequenom's homogeneous Mass-Extend (hME) Genotyping system. Bidirectional probes and primers were designed using Sequenom MassARRAY Typer software (v 4.0), and hME genotyping was performed using 5 ng of unamplified genomic DNA template per assay pool (maximum of four assays per pool).
Immunohistochemistry. Tissue sections were deparaffinized and rehydrated using xylene and graded alcohols. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in 100% ethanol (1:1; 15 min). Antigen retrieval was performed with Dako Target Retrieval Solution, pH 6.0, and pressure cooker treatment (120 ± 2 °C, 15 ± 5 psi) for 45 s. Sections were incubated with primary antibodies against GAB1 (Abcam, ab27439; 1:100 dilution for 45 min), Ki67 (Vector Lab, VP-451; 1:2,500 dilution for 45 min) or Stathmin npg
